Autoimmunity reviews最新文献

{"title":"Authors' response to “comment on ‘systemic lupus erythematosus and male reproductive health: A systematic review and meta-analysis’”","authors":"Qingmiao Zhu , Xiaolong Li , Ting Zhao","doi":"10.1016/j.autrev.2025.103884","DOIUrl":"10.1016/j.autrev.2025.103884","url":null,"abstract":"","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103884"},"PeriodicalIF":9.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of γδ T cells and CAR-γδ T cell therapy in autoimmune diseases","authors":"Tengyue Wang ,&nbsp;Hongli Wang ,&nbsp;Rui Lv ,&nbsp;Chengping Wen ,&nbsp;Mingzhu Wang ,&nbsp;Lin Huang","doi":"10.1016/j.autrev.2025.103883","DOIUrl":"10.1016/j.autrev.2025.103883","url":null,"abstract":"<div><div>Autoimmune diseases represent a major global health challenge, imposing substantial economic, social, and personal burdens on human society. γδ T lymphocytes are a unique T cell subset that bridges innate and adaptive immunity, demonstrating remarkable characteristics in immune regulation and inflammatory modulation. In this context, Chimeric Antigen Receptor (CAR)-γδ T cell therapy emerges as a promising immunotherapeutic strategy with transformative potential in addressing autoimmune disorders. This review comprehensively explores the multifaceted roles of γδ T lymphocytes in autoimmune pathogenesis, highlighting their distinctive functions and properties. It discusses the potential and advantages of applying γδ T cells to CAR-T cell therapy, elucidating the prospects of treating autoimmune diseases through CAR-γδ T cell therapy in the future.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103883"},"PeriodicalIF":9.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycometabolic reprogramming of immune cells in autoimmune diseases","authors":"Jin Lin ,&nbsp;Fan Yang ,&nbsp;Yanyi Zheng ,&nbsp;Xianglin Wang ,&nbsp;Xiaoli Fan ,&nbsp;Li Yang","doi":"10.1016/j.autrev.2025.103876","DOIUrl":"10.1016/j.autrev.2025.103876","url":null,"abstract":"<div><div>Autoimmune diseases (ADs) are a classification of disorders that occur owing to the breakdown of immunological tolerance to self-antigens, leading to an immune response to these antigens and associated bodily harm. The pathogenesis and etiology of these diseases remain unclear. A growing body of research indicates that metabolic reprogramming of immune cells is crucial for immunological control. In particular, glycolysis, a crucial metabolic process in cells, is reconfigured to influence the phenotypic and function of immune cells, therefore playing a role in the onset and progression of ADs. This review elaborates on the involvement of glycometabolic reprogramming in ADs and explores the function of glycometabolic reprogramming in immune cells throughout disease progression. Furthermore, we examine the principal targets implicated and their influence on disease advancement. Finally, we provide a brief summary and outlook of studies related to glycometabolic reprogramming of immune cells in ADs, aiming to guide therapeutic strategies for these diseases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103876"},"PeriodicalIF":9.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC)","authors":"Nantakarn Pongtarakulpanit ,&nbsp;Shiri Keret ,&nbsp;Vaidehi Kothari ,&nbsp;Francisca Bozán ,&nbsp;Chengappa Kavadichanda ,&nbsp;Akira Yoshida ,&nbsp;Valérie Leclair ,&nbsp;Anuradha Bishnoi ,&nbsp;Kaveh Ardalan ,&nbsp;Edoardo Conticini ,&nbsp;Ting-Yuan Lan ,&nbsp;Océane Landon-Cardinal ,&nbsp;Iris Y.K. Tang ,&nbsp;Silvia Rosina ,&nbsp;Belina Y. Yi ,&nbsp;James B. Lilleker ,&nbsp;Eduardo Dourado ,&nbsp;Prateek C. Gandiga ,&nbsp;Rohit Aggarwal","doi":"10.1016/j.autrev.2025.103879","DOIUrl":"10.1016/j.autrev.2025.103879","url":null,"abstract":"<div><div>Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare systemic autoimmune rheumatic diseases. Despite advances in treatment, the definition of remission and low disease activity (LDA) in IIM remains inconsistent and lacks consensus and validation. This review summarizes existing published definitions, achievement rates, and predictive factors of remission/LDA in adult IIM, focusing on dermatomyositis (DM), polymyositis (PM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathies (IMNM). Our literature review revealed a wide variability in remission definitions, incorporating physician assessment, muscle strength, laboratory normalization, and medication tapering or discontinuation. Some studies defined “remission on medication”, while others required complete treatment cessation. Most definitions required a minimum duration of six months. Organ-specific remission (including for the skin, lung, and muscle domains) was inconsistently addressed. LDA has been less extensively studied in IIM, with the myositis disease activity assessment visual analog scales (MYOACT) being the only measure applied to DM. Remission rates varied widely, with stricter criteria yielding lower rates. Factors associated with remission included younger age, early immunosuppressive treatment, non-severe muscle involvement, the absence of myositis-specific autoantibodies (MSA), although some studies reported positivity for certain MSA were associated with remission. Conversely, remission was less likely for patients with PM, overlap myositis, and those positive for anti-TIF1-γ or Ku autoantibodies. Standardized remission criteria incorporating physician assessment, patient assessment, organ-specific parameters, laboratory assessments, and sustained remission duration are essential for harmonizing clinical and research evaluations in IIM. Establishing uniform definitions will improve therapeutic outcome assessments and facilitate meaningful comparisons in clinical trials and real-world practice.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103879"},"PeriodicalIF":9.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The FOXO1-SIRT1 axis in ankylosing spondylitis: A cross-platform regulator linking immunometabolism, oxidative stress, and bone remodeling","authors":"Xuhong Zhang,&nbsp;Lu Jia,&nbsp;Xueni Lin,&nbsp;Lamei Zhou","doi":"10.1016/j.autrev.2025.103878","DOIUrl":"10.1016/j.autrev.2025.103878","url":null,"abstract":"<div><div>Ankylosing spondylitis (AS) is a chronic immune-mediated disorder defined by the paradoxical coupling of inflammatory bone erosion and ectopic new bone formation. Recent studies implicate the Forkhead box O1 (FOXO1)-Sirtuin 1 (SIRT1) signaling axis as a systems-level regulator integrating immune metabolism, redox balance, and skeletal remodeling. FOXO1 and SIRT1 cooperatively regulate immune tolerance, redox balance, and skeletal homeostasis via transcriptional, epigenetic, and metabolic pathways.</div><div>This review delineates the cross-platform roles of the FOXO1-SIRT1 axis across three interrelated modules: regulation of immune cell metabolism and polarization; redox sensing and organelle quality control via autophagy and mitophagy; and coordination of osteoblast – osteoclast dynamics in inflammatory microenvironments. Dysregulation of this axis disrupts immuno-metabolic equilibrium and promotes pathological ossification, contributing to the dual pathology of AS.</div><div>We further discuss emerging therapeutic strategies – ranging from SIRT1 activators and anti -Interleukin-17 A (IL-17 A) biologics to histone deacetylase inhibitors – that converge mechanistically on FOXO1-SIRT1 signaling. These translational approaches underscore the axis's potential as a cross-domain integrator of immune and skeletal homeostasis, and as a promising target for precision intervention in AS.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103878"},"PeriodicalIF":9.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells","authors":"M. Mané-Damas ,&nbsp;A.K. Schöttler ,&nbsp;F. Marcuse ,&nbsp;P.C. Molenaar ,&nbsp;T. Mohile ,&nbsp;J.G.J. Hoeijmakers ,&nbsp;M. Hochstenbag ,&nbsp;J. Damoiseaux ,&nbsp;J.G. Maessen ,&nbsp;M. Abdul-Hamid ,&nbsp;A. zur Hausen ,&nbsp;M.H. de Baets ,&nbsp;M. Losen ,&nbsp;P. Martinez-Martinez","doi":"10.1016/j.autrev.2025.103875","DOIUrl":"10.1016/j.autrev.2025.103875","url":null,"abstract":"<div><div>Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder where the neuromuscular transmission is impaired, causing symptoms of skeletal muscle weakness and fatigue. The presence of autoantibodies against the muscle nicotinic acetylcholine receptor (AChR) is the most prevalent cause of MG. Abnormalities in the thymus are common in AChR-MG, and thymectomy has proven to be therapeutically beneficial. Up to 30 % of AChR-MG patients have also thymoma. Moreover, patients with thymoma without MG are more prompt to develop MG compared to the general population.</div><div>Autoantibodies in AChR-MG damage the postsynaptic membrane of the neuromuscular junction (NMJ) and cause muscle weakness by impairing synaptic transmission because of the depletion of the AChRs and destruction of the NMJ. The pathogenic autoantibody levels vary greatly between patients. In contrast, in individual patients changes in autoantibody levels correlate well with disease severity. A small selection of patients has been used to exemplify the individual relationship between autoantibody levels and disease progression. The study of the effector functions of the autoantibodies and the compensatory mechanisms at the NMJ are important to select the best treatment strategy for each patient. Even though classical immunomodulatory treatments are effective in many patients, around 10–20 % of patients do not respond to current therapies. This may be attributed to the production of autoantibodies by different circulating cells including mature B and long-lived plasma cells, which are resistant to most commonly used immunosuppressive drugs. Hence, novel therapies specifically targeting plasma cells might be a suitable therapeutic approach for selected refractory patients.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103875"},"PeriodicalIF":9.2,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The roles of transient receptor potential vanilloid in autoimmune diseases","authors":"Yuezheng Xiao ,&nbsp;Yue Xin ,&nbsp;Kai Shen ,&nbsp;Ming Yang ,&nbsp;Haijing Wu","doi":"10.1016/j.autrev.2025.103872","DOIUrl":"10.1016/j.autrev.2025.103872","url":null,"abstract":"<div><div>The transient receptor potential vanilloid (TRPV) is a family of tetrameric cation channels, expressed in various tissues and cell types. It includes thermosensitive isoforms (TRPV1–4) and calcium-permeable members (TRPV5–6). In the context of autoimmune diseases, TRPV channels have been firmly established as pivotal regulators that bridge changes in the cellular environment to the immune system.</div><div>Originally identified for their roles in thermosensation and nociception, these polymodal sensors have now emerged as crucial determinants of immune cell function. They are capable of converting chemical signals, temperature fluctuations, and mechanical forces into calcium-mediated signal transduction pathways. Mounting evidence indicates that dysregulated TRPV channel activity leads to pathological calcium influx, triggering a signaling cascade that reprograms the functions of key immune cells and modulates pain and itch signaling through neuroimmune crosstalk. These cascades amplify inflammatory responses, exacerbate autoimmune pathology, promote inflammatory cytokine release, and modulate pain/itch signaling via neuroimmune crosstalk.</div><div>Specifically, these mechanisms are instrumental in the progression including autoimmune disorders, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), multiple sclerosis (MS), psoriasis, and atopic dermatitis (AD). Novel therapeutic strategies are emerging, aiming to modulate TRPV activity in autoimmune conditions. Approaches include suppressing hyperactive channels and leveraging their immunoregulatory potential. Promising preclinical results have highlighted that TRPV channels exhibit dual translational potential in mechanistic research of autoimmune diseases, integrating precise targeting with dynamic monitoring capabilities. However, translating these findings into clinical applications faces significant challenges, including differential effects on neuronal and immune signaling, as well as systemic side effects caused by disruptions to physiological homeostasis.</div><div>This narrative review discuss how TRPV channel signaling has enhanced our understanding of autoimmune disease initiation. By dissecting how TRPV-mediated immune dysregulation drives pathological immune responses, we seek to offer novel mechanistic insights to inform the development of more effective and comprehensive treatment strategies for autoimmune diseases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103872"},"PeriodicalIF":9.2,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion of circulating T follicular helper cells in peripheral blood of systemic lupus erythematosus patients: A systematic review and meta-analysis","authors":"Futai Feng ,&nbsp;Ziyan Wu ,&nbsp;Honglin Xu ,&nbsp;Yongzhe Li ,&nbsp;Shulan Zhang","doi":"10.1016/j.autrev.2025.103874","DOIUrl":"10.1016/j.autrev.2025.103874","url":null,"abstract":"<div><h3>Objectives</h3><div>Dysregulation of circulating follicular helper T (cTfh) cells plays a key role in the breakdown of immune tolerance and the pathogenesis of antibody-mediated autoimmune diseases, including systemic lupus erythematosus (SLE). This study aims to evaluate the proportions of cTfh cells and their potential pathogenic mechanisms in the peripheral blood of SLE patients through a systematic review and meta-analysis.</div></div><div><h3>Methods</h3><div>Systematic search and review were conducted across PubMed, Cochrane Library, EMBASE, and Web of Science to identify relevant studies. A meta-analysis was performed to compare the proportions of cTfh cells and their subsets between SLE patients and healthy controls (HC). Subgroup analyses were conducted based on the markers used for defining cTfh cells and geographical regions.</div></div><div><h3>Results</h3><div>The meta-analysis revealed a significantly higher proportion of cTfh cells in SLE patients compared to HC (SMD 0.904, [0.620, 1.188], <em>p</em> &lt; 0.01). Subgroup analyses showed a consistent increase in cTfh cells in SLE across different markers. Geographically, both Asian (SMD 1.005, [0.608, 1.402], <em>p</em> &lt; 0.01) and non-Asian populations (SMD 0.708, [0.428, 0.988], <em>p</em> &lt; 0.01) demonstrated elevated cTfh cell proportions in SLE. A trend toward a decrease in Tfh1 cells and an increase in Tfh17 cells was observed, though neither reached statistical significance.</div></div><div><h3>Conclusion</h3><div>Our study demonstrates that cTfh cells proportions are significantly elevated in SLE patients, supporting their role in the pathogenesis of SLE. These findings suggest that cTfh cells could serve as potential biomarkers for SLE and therapeutic targets for treatment.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103874"},"PeriodicalIF":9.2,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in rheumatoid arthritis among U.S. women aged 20 to 44 years, 2001 to 2023","authors":"Yuhui Zhao ,&nbsp;Weilu Cui ,&nbsp;Yayun Han ,&nbsp;Minjing Chang","doi":"10.1016/j.autrev.2025.103873","DOIUrl":"10.1016/j.autrev.2025.103873","url":null,"abstract":"","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103873"},"PeriodicalIF":9.2,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy","authors":"Angeliki Zoi Lignou ,&nbsp;Konstantinos D. Vassilakis ,&nbsp;Xenofon Baraliakos ,&nbsp;Petros P. Sfikakis ,&nbsp;Jacques-Eric Gottenberg ,&nbsp;George E. Fragoulis","doi":"10.1016/j.autrev.2025.103865","DOIUrl":"10.1016/j.autrev.2025.103865","url":null,"abstract":"<div><h3>Background</h3><div>Immune-mediated inflammatory diseases (IMID) include rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), Crohn's disease (CD), ulcerative colitis (UC), and psoriasis (PsO). While biologic (b) and targeted synthetic (ts) DMARDs are effective, nearly 60 % of patients fail to achieve low disease activity status. Combination targeted therapy (CTT) using concomitantly two different b- or ts-DMARDs has been explored, but results on safety and efficacy are unclear.</div></div><div><h3>Objective</h3><div>To systematically review the literature on CTT in IMID.</div></div><div><h3>Methods</h3><div>Following the PICO framework, we included literature of adult patients (≥18 years) with IMID receiving CTT. Three databases (PubMed, Scopus, Epistemonikos) were searched up to June 2024. Studies in non-English, pediatric populations, and non-approved treatments were excluded. Risk of bias was assessed using approved tools.</div></div><div><h3>Results</h3><div>Of 2038 records, 70 studies (6 RCTs, 11 cohorts, 22 case series, 31 case reports) involving 1200 patients were analyzed. About 75 % of them demonstrated low risk of bias. The most studied combinations were TNFi+IL/23i, JAKi+bDMARDs, and vedolizumab+TNFi. Approximately 40-60 % of patients with PsA, axSpA, and IBD with refractory disease improved with TNFi+IL/23i CTT. About half of patients with inflammatory arthritis and up to 80 % of IBD cases benefited with JAKi+bDMARD CTT, whereas favorable outcomes were observed in 30-50 % of IBD patients following Vedolizumab+TNFi CTT. Safety profiles were generally acceptable, without emerging signals so far.</div></div><div><h3>Conclusion</h3><div>CTT benefits about half of refractory IMID patients, particularly TNFi/IL-23i, JAKi/bDMARD, and vedolizumab/TNFi combinations, without raising significant safety issues. Further research is needed to clarify safety and efficacy across diseases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103865"},"PeriodicalIF":9.2,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}